Market Overview - The Shanghai Composite Index closed at 4011.45 points, above the five-day moving average, with an increase of 1.07% [1] - The total trading volume of A-shares reached 1.960478 trillion yuan [1] Stock Performance - A total of 1880 A-shares have prices that surpassed the five-day moving average [1] - Stocks with significant deviation rates include: - BeiYikang (证券代: 920199) with a deviation rate of 18.85%, closing at 44.96 yuan, up 29.98% [1] - WeiSi Medical (证券代: 688580) with a deviation rate of 15.01%, closing at 58.08 yuan, up 20.00% [1] - ChengYiTong (证券代: 300430) with a deviation rate of 14.78%, closing at 23.06 yuan, up 19.98% [1] Additional Notable Stocks - Other notable stocks with high deviation rates include: - GuanHao Biological (证券代: 300238) at 14.72% [1] - DiNaiKe (证券代: 300884) at 14.64% [1] - MeiHao Medical (证券代: 301363) at 14.46% [1] - Stocks with lower deviation rates that just crossed the five-day moving average include: - ChenZhan Optoelectronics (证券代: 688767) at 12.64% [1] - SaiNuo Medical (证券代: 688108) at 12.19% [1]

Core Viewpoint - The A-share market experienced a significant surge on January 5, 2026, driven by the brain-computer interface (BCI) sector, with the index rising over 12% and multiple stocks hitting their daily limit up [1] Group 1: Market Performance - On the opening day of the A-share market, stocks related to brain-computer interfaces saw a collective rally, with stocks like BeiYikang (920199.BJ) hitting a 30% limit up and others such as Botao Bio (688767.SH) and Sanbo Neuroscience (301293.SZ) reaching 20% limit up [1] - A total of 11 stocks in the BCI sector experienced a 20% limit up, indicating strong investor interest and market momentum [1] Group 2: Technological Developments - The surge in the BCI sector was catalyzed by news of mass production of BCI devices by Elon Musk's company, Neuralink, expected to begin in 2026, which includes advancements in surgical procedures [1] - Neuralink's device will feature electrodes that can penetrate the dura mater without removal, marking a significant technological breakthrough [1] Group 3: Domestic Developments - In China, several companies are emerging that parallel Neuralink's technological approach, with Guotai Junan Securities declaring 2025 as the year for clinical trials of invasive and semi-invasive BCIs [2] - Companies like Borui Kang have completed clinical trials, with expectations for regulatory approval in 2026, while other firms are also making progress in BCI technology [2] Group 4: Market Projections - Open Source Securities predicts that BCI technology will redefine human-robot interaction and is expected to commercialize by 2026, expanding from medical applications to AI and robotics [3] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, indicating strong future growth potential [3]

证券时报·数据宝统计，截至今日上午10:28，上证综指4004.00点，收于五日均线之上，涨跌幅0.89%， A股总成交额为13939.72亿元。到目前为止，今日有1799只A股价格突破了五日均线，其中乖离率较大 的个股有倍益康、伟思医疗、诚益通等，乖离率分别为18.85%、15.01%、14.78%；天和防务、利君股 份、中船科技等个股乖离率较小，刚刚站上五日均线。 （文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 920199 | 倍益康 | 29.98 | 11.91 | 37.83 | 44.96 | 18.85 | | 688580 | 伟思医 | 20.00 | 6.89 | 50.50 | 58.08 | 15.01 | | | 疗 | | | | | | | 300430 | 诚益通 | 19.98 | 15.71 | 20.09 | 23.06 | ...

政策端也持续加码支持。国家药监局近期在北京召开脑机接口医疗器械工作推进会，明确表示将加快相 关产品的审评审批流程，推动创新器械更快上市应用。 国金证券指出，在医疗器械创新政策密集落地 背景下，脑机接口作为前沿交叉领域，正迎来从科研验证向临床及消费场景拓展的关键窗口期。 （文章来源：每日经济新闻） 医疗器械ETF（562600）大涨4.36%。截止2025年12月30日，医疗器械ETF脑机接口含量达20.91%。 消息面上，行业迎来多重催化。特斯拉CEO埃隆·马斯克近日在社交媒体透露，其旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备的"大规模生产"。这一表态被市场视为该技术迈向商业化的重 要信号。 与此同时，由OpenAI首席执行官Sam Altman联合创立的脑机接口初创公司Merge Labs宣布将分拆为独 立实体，专注于开发基于超声波的非侵入式脑信号读取技术。该方案无需植入电极，即可实现对大脑活 动的大范围、高精度解读，有望大幅降低技术门槛与临床风险。 早盘脑机接口概念小幅高开，随后震荡上行，截止10点57分，乐普医疗、美好医疗、翔宇医疗、伟思医 疗、迈普医学封板涨停。 ...

科创板个股中，截至发稿上涨的有506只，下跌的有91只，涨停的有翔宇医疗、伟思医疗、麦澜德等， 跌幅居前的有铂力特、富吉瑞、步科股份等，分别下跌9.17%、7.81%、6.05%。 资金面上，伟思医疗上一交易日主力资金净流入257.84万元，近5日净流入2054.10万元。 1月5日盘中科创板股伟思医疗涨停，截至09:56，股价报58.08元，成交2.79亿元，换手率5.20%，振幅 12.77%。 融资融券数据显示，该股最新（12月31日）两融余额为1.81亿元，其中，融资余额为1.81亿元，较上一 个交易日减少266.96万元，降幅为1.45%；融券余额为9.68万元，较上一个交易日减少20.45万元，降幅 为67.87%。近10日两融余额合计增加635.15万元，增幅为3.63%，其间融资余额增长3.58%，融券余额增 长441.14%。 从机构评级来看，近一个月该股获1家机构买入评级。12月25日西部证券发布的研报给予公司增持评 级。（数据宝） （文章来源：证券时报网） ...

对此，开源证券指出，Neuralink的规模化生产预期+自动化手术方案，以及Merge布局新一代超声波脑 机接口技术具备双重意义。（1）标志着脑机接口从临床验证阶段开始向商业化规模化阶段迈进，推动 脑机接口从"医疗试验工具"到"可普及产品"的落地。2）未来随着技术方案成熟度的进一步提升，也将 为Neuralink脑机接口与特斯拉Optimus人形机器人的协同应用奠定基础。 该机构表示，脑机接口行业正处于技术突破、政策支持、机器人生态协同预期等多重因素驱动下的高增 蓄势期，根据Precedence Research数据，预计到2034年全球脑机接口市场规模将增长到约124亿美元， 2025年—2034年CAGR为17%。在近期Neuralink规模化量产预期和技术突破的催化下，A股脑机接口相 关标的也有望受益。 人脑工程概念5日盘中强势拉升，截至发稿，倍益康30%涨停，三博脑科、翔宇医疗、伟思医疗、美好 医疗等均涨停，熵基科技涨超18%。 消息面上，马斯克近日在社交媒体上表示，旗下Neuralink将在2026年启动脑机接口设备大规模生产，并 同步推进流程高度精简、几乎完全自动化的手术方案，最关键的突破在于，设 ...

消息面上，大摩预期，今年中国人形机器人可出货1.4万台，未来数年将逐年翻倍增长，2034年突破百 万台。 另据每经报道，当地时间2025年12月31日，埃隆.马斯克在社交媒体上表示，其脑机接口公司Neuralink 将于2026年开始对脑机接口设备进行"大规模生产"，还将在脑机植入方式上实现创新。 1月5日电，机器人概念反复活跃，倍益康、翔宇医疗、伟思医疗、熵基科技等涨20%，五洲新春走出4 连板，斯菱智驱涨超15%，双双续创历史新高，汉威科技、蓝思科技、雷迪克、博杰股份等冲高。 | 序号 | 代码 | 名称 | 0 | 最新 | 涨幅% J | | --- | --- | --- | --- | --- | --- | | 1 | 920199 | 倍益康 | 事 | 44.96 | 29.98 | | 2 | 688626 | 翔宇医疗 | 1 | 72.60 | 20.00 | | 3 | 688580 | 伟思医疗 | | 58.08 | 20.00 | | 4 | 301330 | 嫡基科技 | 1 | 39.66 | 20.00 | | 5 | 300753 | 爱朋医疗 | 1 | 33.30 ...

每经AI快讯，1月5日，沪指高开0.46%，深成指高开0.80%，创业板指高开0.84%，人脑工程、贵金属、 石油石化等板块指数涨幅居前。脑机接口概念表现活跃，创新医疗涨停，美好医疗、三博脑科20cm涨 停，倍益康、爱朋医疗、翔宇医疗涨超10%，博拓生物、伟思医疗跟涨。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint of the article highlights that Weisi Medical has developed a comprehensive product matrix of rehabilitation robots that covers both upper and lower limbs, integrating various therapeutic technologies [2] - The company aims to provide high-quality solutions for rehabilitation needs, specifically targeting neurological, motor, critical care, and chronic diseases in the elderly [2] - Weisi Medical's approach focuses on meeting the precise demands of improvement-oriented rehabilitation through advanced technology [2]

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]